FindTrial
Sign In

Clinical and dermatoscopic changes in patients with moderate to severe plaque psoriasis treated with Secukinumab

Clinical and dermatoscopic changes in patients with moderate to severe plaque psoriasis treated with Secukinumab

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082361
Enrollment
Unknown
Registered
2024-03-27
Start date
2023-07-13
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Case series:None

Sponsors

The First People's Hospital of Jingzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Psoriasis was confirmed by pathological biopsy; ? The lesions showed plaque psoriasis; ? The degree of skin lesions was moderate to severe (PASI > 10).

Exclusion criteria

Exclusion criteria: (1) Concomitant severe active infections (e.g., active tuberculosis, etc.); (2) Concomitant tuberculosis, hepatitis B, hepatitis C, AIDS, etc; (3) Concomitant tumor lesions; (4) Recently planning to conceive or already pregnant; (5) Other variants of psoriasis, such as punctate, pustular, erythrodermic, etc.; (6) Patients demonstrating loss of follow-up; (7) Severe liver and kidney dysfunction; (8) Treatment interruption;

Design outcomes

Primary

MeasureTime frame
Vascular diameter;Vascular density;PASI score;—

Countries

China

Contacts

Public ContactFaqing Huang

The First People's Hospital of Jingzhou

rumo-huang@163.com+86 181 6313 8880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026